This suggests the inhibitors of the pentose phosphate system, including such benfooxythiamine, could be a viable therapy choice for COVID-19, both alone and in conjunction using existing medications.
The medicine also improved the antimicrobial activities of ‘2-deoxy-D-glucose,’ a treatment that alters the recipient cell’s metabolism to inhibit pathogen growth, according to the study.
A Possible Novel COVID-19 Therapy Has Been Discovered
The viral infection of coronavirus was beyond the expectation of experts, and that is why when it spread, there was no specific mitigation plan ready with them.
However, now they have learned a lesson and go for various options that can help prevent the spread of infection. This new option is believed to be more effective and than that are used previously as far as the treatment is concerned.
SARS-CoV-2 proliferation is inhibited, and pathogens did not generate coronaviruses when the medication benfooxythiamine and antagonist of this mechanism has been used. Scientists had discovered a possible new medication that stops SARS-CoV-2, the coronavirus which produces COVID-19, from replicating.
All infections, including coronaviruses, enter cells then reprogram themselves to make new viruses in need to propagate. Cells treated by SARS-CoV-2 can only generate additional coronaviruses if their metabolism pentose phosphate route is engaged, according to the findings.
Professor Martin Michaelis said, “This is a breakthrough in the research of COVID-19 treatment. Since resistance development is a big problem in the treatment of viral diseases, having therapies that use different targets is very important. It provides further hope for developing the most effective treatments for COVID-19.”
Professor Jindrich Cinatl said, “Targeting virus-induced changes in the host cell metabolism is an attractive way to interfere specifically with the virus replication process.”
Furthermore, the antiretroviral action of benfooxythiamine varies from other COVID-19 medications like remdesivir & molnupiravir. As a result, infections that are immune to such antibiotics could be susceptible to benfooxythiamine.
The majority of medical papers on COVID-19 therapy focused on empirical therapies & practical exposure. The researcher investigated the effects of chloroquine with hydroxychloroquine in the therapy of COVID-19 in approximately 100 cases and ten institutions in the year 2020.
The data revealed the chloroquine phosphate is beneficial in avoiding pneumonia exacerbations, reducing lung participation in radiological results, encouraging virus-negative conversions & reducing the illness duration. Furthermore, at medical levels, no significant side effects are identified.
Therapy of 51 COVID-19 individuals using traditional medicine, interferon, Lopinavir, Ritonavir with brief (3 to 5 days) corticosteroids also was effective as per Jian-ya et al., with 50 people recovering and being discharged.
Scientists also found that giving non-ICU individuals moxifloxacin, lopinavir, and interferon, as well as adding methylprednisolone to the aforesaid medication for Patients found in 26 patients getting released from ICU and 16 patients having freed from the clinic.
Brief, modest glucocorticoid (160 mg/day) with immunoglobulin (20 g/day) decreased lung injury, normalized lymphocyte numbers, pulse rate, C-reactive protein concentrations, as well as oxygen score in 10 COVID-19 individuals, according to scientists.
On the other side found that corticosteroid treatment and gamma globulin injection enhanced death in 416 COVID-19 individuals and seemed to be helpful only in individuals with reduced lymphocyte levels. The use of corticosteroids in COVID-19 individuals is currently controversial, as per the medical findings presented.
According to their benefits described in medical research, Arbidol hydrochloride, interferon, & Thalidomide plus Methylprednisolone may be utilized in addition to the medications presently indicated to manage COVID-19.
More research is required, though, to establish the usage of corticosteroids since there are mixed stories on their effectiveness. Remdesivir, Atazanavir, Saquinavir, & Metoprolol, as well as Tocilizumab, which are included in Table 1, could be used as COVID-19 therapies if drugs show to be successful in clinical and animal investigations.
